Payment overview · 2025
General Payments
$348.37
15 reported records · 9 companies
Healthcare provider profile · identity verified
Jason P. Lee, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MECHANICSVILLE, VA · NPI 1295767846
Verified facts
What the public records show
CMS Open Payments records show Jason P. Lee, M.D. received $348.37 in general payments during 2025 across 15 reported records.
LEO Pharma Inc. accounted for 24.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| LEO Pharma Inc. | Unresolved — no canonical attribution shown | $84.69 | 24.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $60.62 | 17.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $54.02 | 15.5% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $39.08 | 11.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.51 | 9.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.18 | 8.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 5.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.78 | 4.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.64 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $329.52 | 14 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ANZUPGO Normalized: anzupgo |
Drug | LEO Pharma Inc. | $84.69 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $60.62 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $39.08 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $31.51 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $30.24 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.18 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.18 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $23.78 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 141 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
141 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1204 | 346 |
| Amlodipine Besylate | Amlodipine Besylate | 901 | 262 |
| Hydrochlorothiazide | Hydrochlorothiazide | 525 | 149 |
| Lisinopril | Lisinopril | 407 | 112 |
| Losartan Potassium | Losartan Potassium | 393 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 349 | 91 |
| Pravastatin Sodium | Pravastatin Sodium | 336 | 94 |
| Omeprazole | Omeprazole | 324 | 93 |
| Ezetimibe | Ezetimibe | 303 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 284 | 85 |
| Metformin Hcl Er | Metformin Hcl | 261 | 76 |
| Furosemide | Furosemide | 248 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 239 | 68 |
| Gabapentin | Gabapentin | 233 | 64 |
| Metformin Hcl | Metformin Hcl | 221 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 184 | 59 |
| Simvastatin | Simvastatin | 167 | 40 |
| Carvedilol | Carvedilol | 164 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 44 |
| Sertraline Hcl | Sertraline Hcl | 149 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 148 | 35 |
| Potassium Chloride | Potassium Chloride | 147 | 48 |
| Tramadol Hcl | Tramadol Hcl | 145 | 36 |
| Eliquis | Apixaban | 141 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 126 | 33 |
| Glimepiride | Glimepiride | 124 | 38 |
| Allopurinol | Allopurinol | 113 | 35 |
| Lorazepam | Lorazepam | 108 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 33 |
| Atenolol | Atenolol | 102 | 25 |
| Ozempic | Semaglutide | 102 | 21 |
| Alprazolam | Alprazolam | 95 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 94 | 25 |
| Montelukast Sodium | Montelukast Sodium | 93 | 31 |
| Famotidine | Famotidine | 92 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 25 |
| Trazodone Hcl | Trazodone Hcl | 85 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 84 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 34 |
| Methylprednisolone | Methylprednisolone | 81 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 15 |
| Alendronate Sodium | Alendronate Sodium | 76 | 19 |
| Azithromycin | Azithromycin | 74 | 62 |
| Ondansetron Odt | Ondansetron | 74 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 72 | 32 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 71 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 69 | 23 |
| Clonazepam | Clonazepam | 68 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 66 | 21 |
| Warfarin Sodium | Warfarin Sodium | 66 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 65 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 64 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 18 |
| Diazepam | Diazepam | 60 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 59 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 25 |
| Donepezil Hcl | Donepezil Hcl | 56 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 15 |
| Pregabalin | Pregabalin | 53 | 13 |
| Valsartan | Valsartan | 53 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 52 | 14 |
| Jardiance | Empagliflozin | 52 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 50 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 11 |
| Felodipine Er | Felodipine | 47 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Finasteride | Finasteride | 44 | 17 |
| Amoxicillin | Amoxicillin | 42 | 38 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 41 | 11 |
| Baclofen | Baclofen | 40 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Glipizide | Glipizide | 38 | 12 |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 28 |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 31 | 12 |
| Irbesartan | Irbesartan | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Repatha Syringe | Evolocumab | 30 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Repatha Sureclick | Evolocumab | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 28 | suppressed |
| Acyclovir | Acyclovir | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | 16 |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Prednisone | Prednisone | 23 | 12 |
| Cephalexin | Cephalexin | 22 | 15 |
| Brilinta | Ticagrelor | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 19 |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Nystatin | Nystatin | 21 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 18 |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Yuvafem | Estradiol | 13 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lexapro | Escitalopram Oxalate | 12 | suppressed |
| Lopid | Gemfibrozil | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $348.37 · 15 records | LEO Pharma Inc. | ANZUPGO, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, INSPIRE, JARDIANCE, NURTEC ODT, QULIPTA, UBRELVY, VYNDAQEL | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error